Camille Georges Wermuth

USPTO Granted Patents = 16 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 61(Granted Patents)

Location History:

Illkirch, FR (2009)
Strasbourg, FR (1994 - 2014)
Srasbourg, FR (2015)

Company Filing History:

Janssen Pharmaceutica Nv

patents

2 out of 5,094

Centre National De La Recherche Scientifique

Prestwick Pharmaceuticals, Inc.

Centre D'etudes Experimentales Et Cliniques De Physio-Biologie De

patents

where one patent can have more than one assignee

Years Active: 1994-2015

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8993573 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2015-03-31),

2. 8835435 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2014-09-16),

3. 8450302 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2013-05-28),

4. 8404683 - Inhibitors of the interaction between MDM2 and P53 (2013-03-26),

5. 8377961 - Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53 (2013-02-19),

6. 8110591 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors (2012-02-07),

7. 8088795 - Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 (2012-01-03),

8. 8071590 - 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials (2011-12-06),

9. 7834016 - Inhibitors of the interaction between MDM2 and p53 (2010-11-16),

10. 7718676 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors (2010-05-18),

11. 7713965 - 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials (2010-05-11),

12. 7514454 - Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders (2009-04-07),

13. 7488755 - Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid (2009-02-10),

14. 7423055 - 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases (2008-09-09),

15. 6344470 - Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same (2002-02-05),

Title: **Camille Georges Wermuth: A Pioneer in Pharmaceutical Innovations**

Introduction

Camille Georges Wermuth, an accomplished inventor based in Illkirch, France, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, Wermuth has been at the forefront of developing innovative compounds that hold promise for treating various human and animal diseases.

Latest Patents

Wermuth's latest patents focus on novel compounds known as 2-(3-aminoaryl) amino-4-aryl-thiazoles and their applications as c-kit inhibitors. These compounds are designed to selectively modulate and inhibit signal transductions mediated by specific tyrosine kinases, which are implicated in numerous diseases, including cell proliferative metabolic, allergic, and degenerative disorders. Notably, these compounds exhibit potent and selective inhibition capabilities, showcasing Wermuth's commitment to advancing medical science.

Career Highlights

Throughout her career, Camille Georges Wermuth has worked with esteemed companies such as Ab Science and Janssen Pharmaceutica NV. Her experience in these organizations has allowed her to refine her expertise and contribute significantly to the pharmaceutical industry.

Collaborations

Wermuth has collaborated with notable colleagues, including Bruno Giethlen and Alain Moussy. These partnerships have been essential in fostering innovative research and development efforts, leading to breakthroughs in new therapeutic approaches.

Conclusion

Camille Georges Wermuth is a trailblazer in pharmaceutical innovations, with her patents paving the way for future therapeutic advances. Through her work, she continues to impact the healthcare industry positively, demonstrating the vital role of inventors in enhancing medical treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.